We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current AVTX market cap is 94.38M. The company's latest EPS is USD -3.0348 and P/E is -0.97.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 236k | 571k | 0 | 0 | 249k |
| Operating Income | -3.75M | -7.66M | -32.77M | -9.57M | -12.86M |
| Net Income | -5.23M | -8.17M | -121.29M | 98.46M | 23.04M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 6.75M | 6.7M | 5.4M | 18.05M | 1.92M |
| Operating Income | -17.39M | -72.84M | -82.15M | -37.44M | -27.35M |
| Net Income | -16.27M | -63.5M | -84.38M | -41.66M | -31.54M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 29.27M | 20.99M | 123.73M | 108.31M | 98.46M |
| Total Liabilities | 14.58M | 13.69M | 224.81M | 110.46M | 75.72M |
| Total Equity | 14.7M | 7.3M | -112.54M | -13.61M | 21.08M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 36.11M | 43.76M | 80.21M | 33.37M | 20.99M |
| Total Liabilities | 15.11M | 19.19M | 57.13M | 44.28M | 13.69M |
| Total Equity | 21M | 24.56M | 23.08M | -10.92M | 7.3M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -27.91M | -30.68M | -6.2M | -22.49M | -34.01M |
| Investing | -133k | -133k | 356k | 356k | 356k |
| Financing | 25.04M | 25.04M | 108.61M | 108.14M | 108.14M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -19.13M | -40.54M | -70.89M | -26.75M | -30.68M |
| Investing | -443k | 11.13M | -113k | -95k | -133k |
| Financing | 12.56M | 44.79M | 106.76M | -14.7M | 25.04M |
| Market Cap | 94.38M |
| Price to Earnings Ratio | -0.97 |
| Price to Sales Ratio | 15.83 |
| Price to Cash Ratio | 4.11 |
| Price to Book Ratio | 4.17 |
| Dividend Yield | - |
| Shares Outstanding | 10.39M |
| Average Volume (1 week) | 127.26k |
| Average Volume (1 Month) | 96.15k |
| 52 Week Change | -20.68% |
| 52 Week High | 34.46 |
| 52 Week Low | 3.9501 |
| Spread (Intraday) | 5.25 (55.26%) |
| Company Name | Avalo Therapeutics Inc |
| Address |
251 little falls drive wilmington, delaware 19808 |
| Website | https://www.avalotx.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
